Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/LPP_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/LPP_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/LPP_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/LPP_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/LPP_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/LPP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/LPP_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/LPP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/LPP_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/LPP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/LPP_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/LPP_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/LPP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003051831 | Oral cavity | NEOLP | intracellular steroid hormone receptor signaling pathway | 27/2005 | 116/18723 | 7.54e-05 | 9.71e-04 | 27 |
GO:002240923 | Oral cavity | NEOLP | positive regulation of cell-cell adhesion | 51/2005 | 284/18723 | 1.50e-04 | 1.72e-03 | 51 |
GO:005109031 | Oral cavity | NEOLP | regulation of DNA-binding transcription factor activity | 72/2005 | 440/18723 | 1.66e-04 | 1.84e-03 | 72 |
GO:004340131 | Oral cavity | NEOLP | steroid hormone mediated signaling pathway | 29/2005 | 136/18723 | 2.17e-04 | 2.29e-03 | 29 |
GO:001059514 | Oral cavity | NEOLP | positive regulation of endothelial cell migration | 28/2005 | 133/18723 | 3.44e-04 | 3.33e-03 | 28 |
GO:003052123 | Oral cavity | NEOLP | androgen receptor signaling pathway | 13/2005 | 44/18723 | 4.99e-04 | 4.42e-03 | 13 |
GO:005109121 | Oral cavity | NEOLP | positive regulation of DNA-binding transcription factor activity | 45/2005 | 260/18723 | 8.06e-04 | 6.39e-03 | 45 |
GO:003362713 | Oral cavity | NEOLP | cell adhesion mediated by integrin | 17/2005 | 72/18723 | 1.29e-03 | 9.43e-03 | 17 |
GO:001059414 | Oral cavity | NEOLP | regulation of endothelial cell migration | 40/2005 | 232/18723 | 1.64e-03 | 1.14e-02 | 40 |
GO:001631122 | Oral cavity | NEOLP | dephosphorylation | 64/2005 | 417/18723 | 1.98e-03 | 1.33e-02 | 64 |
GO:000975515 | Oral cavity | NEOLP | hormone-mediated signaling pathway | 33/2005 | 190/18723 | 3.53e-03 | 2.07e-02 | 33 |
GO:004854518 | Prostate | BPH | response to steroid hormone | 109/3107 | 339/18723 | 9.35e-13 | 8.15e-11 | 109 |
GO:004851110 | Prostate | BPH | rhythmic process | 96/3107 | 298/18723 | 1.88e-11 | 1.31e-09 | 96 |
GO:000762310 | Prostate | BPH | circadian rhythm | 73/3107 | 210/18723 | 1.02e-10 | 6.02e-09 | 73 |
GO:007138316 | Prostate | BPH | cellular response to steroid hormone stimulus | 71/3107 | 204/18723 | 1.72e-10 | 9.79e-09 | 71 |
GO:003052110 | Prostate | BPH | androgen receptor signaling pathway | 23/3107 | 44/18723 | 5.88e-08 | 1.57e-06 | 23 |
GO:003051810 | Prostate | BPH | intracellular steroid hormone receptor signaling pathway | 43/3107 | 116/18723 | 8.48e-08 | 2.12e-06 | 43 |
GO:003052216 | Prostate | BPH | intracellular receptor signaling pathway | 77/3107 | 265/18723 | 2.49e-07 | 5.42e-06 | 77 |
GO:000647010 | Prostate | BPH | protein dephosphorylation | 78/3107 | 281/18723 | 1.53e-06 | 2.63e-05 | 78 |
GO:004340110 | Prostate | BPH | steroid hormone mediated signaling pathway | 45/3107 | 136/18723 | 1.78e-06 | 2.98e-05 | 45 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LPP | SNV | Missense_Mutation | rs749505857 | c.1396G>A | p.Glu466Lys | p.E466K | | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
LPP | SNV | Missense_Mutation | | c.922N>C | p.Gly308Arg | p.G308R | | protein_coding | tolerated(0.11) | possibly_damaging(0.818) | TCGA-A1-A0SH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD |
LPP | SNV | Missense_Mutation | rs756003756 | c.1457G>A | p.Arg486Gln | p.R486Q | | protein_coding | deleterious(0) | possibly_damaging(0.74) | TCGA-A1-A0SM-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LPP | SNV | Missense_Mutation | | c.254N>G | p.Ser85Cys | p.S85C | | protein_coding | tolerated(0.05) | benign(0.276) | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
LPP | SNV | Missense_Mutation | | c.1834N>G | p.Leu612Val | p.L612V | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.974) | TCGA-A8-A083-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LPP | SNV | Missense_Mutation | novel | c.1576N>A | p.Glu526Lys | p.E526K | | protein_coding | deleterious(0) | possibly_damaging(0.57) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LPP | SNV | Missense_Mutation | novel | c.1274N>T | p.Gly425Val | p.G425V | | protein_coding | deleterious(0) | possibly_damaging(0.874) | TCGA-AC-A2QH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
LPP | SNV | Missense_Mutation | | c.1391N>G | p.Tyr464Cys | p.Y464C | | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
LPP | SNV | Missense_Mutation | novel | c.452N>G | p.Ser151Cys | p.S151C | | protein_coding | deleterious(0.02) | possibly_damaging(0.885) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
LPP | SNV | Missense_Mutation | | c.1751N>A | p.Cys584Tyr | p.C584Y | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |